National Comprehensive Cancer Network

Educational Events & Programs

NCCN 5^th Annual Congress: Hematologic Malignancies™

Educational Objectives

Following this program, participants should be able to:

Evolving Strategies for Treating Myeloma

• Discuss current therapeutic strategies for patients with multiple myeloma
• Describe recent clinical trial results regarding therapy for myeloma patients
• List novel agents emerging in the setting of multiple myeloma

Diagnosis and Management of Waldenström’s Macroglobulinemia (WM)

• Discuss the diagnosis and workup of WM
• Describe currently used agents for the treatment of WM

Optimizing Bone Health in Patients with Myeloma

• Describe the manifestations of bone disease and current methods of bone assessment in myeloma

• Discuss current management strategies for myeloma bone disease

• Explain the pathogenesis of myeloma bone disease and novel targets for clinical development

Evolving Treatment Strategies in Chronic Myelogenous Leukemia (CML)

• Describe the data supporting selection of first and succeeding lines of therapy for CML
• Discuss the common toxicities associated with TKI therapy

Hodgkin Lymphoma

• Describe factors that affect the current standard of care for the management of patients with Hodgkin Lymphoma
• Provide examples of regimens that are currently in clinical trials for Hodgkin Lymphoma

Adult T-Cell Leukemia and Lymphoma (ATLL)

• Identify the essential criteria used to confirm a diagnosis of ATLL and the subtypes of ATLL
• Outline the existing and emerging therapy strategies for patients with ATLL

Emerging Treatments for T-Cell Lymphoma

• Describe the mechanism of action and clinical evidence for the recently approved treatment options for relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL)
• Discuss the data from clinical trials evaluating newer agents for the treatment of relapsed or refractory PTCL and CTCL

Hepatitis B Viral (HBV) Reactivation in Patients with Hematologic Malignancies

• Identify the risk factors for HBV reactivation
• List complications resulting from HBV reactivation
• Discuss the currently effective prophylactic measures and emerging management strategies for the management of HBV reactivation

Using Informatics Tools to Guide Therapy in Hematologic Malignancies

• Describe medical informatics applications that support consistent evidence-based care for patients with hematologic malignancies
• Differentiate between treatment recommendations for an average patient and apply those recommendations to the individual patient

New Directions in the Prevention and Management of Venous Thromboembolic Disease (VTE)

• Discuss pathophysiologic factors associated with increased risk of VTE in patients with cancer
• Describe the VTE risks associated with specific hematologic malignancies
• Describe the advantages and disadvantages of anticoagulants (e.g., warfarin; LMWHs) commonly used in the long-term prophylaxis and treatment of VTE
• Summarize evidence from recent clinical studies regarding the efficacy and safety of the new oral anticoagulants in development

Prevention of Infections in Patients with Hematologic Malignancies

• Evaluate infection risk in immunocompromised patients with hematologic malignancies
• Select targeted prophylaxis as appropriate based on type of infection

Myeloid Growth Factors for the Management of Febrile Neutropenia

• Stratify patients undergoing myelosuppressive chemotherapy into risk categories for developing febrile neutropenia
• Evaluate cost effectiveness when determining if prophylactic myeloid growth factors will be useful for patient populations with differing disease states

Management of Disease-Specific Complications in Chronic Lymphocytic Leukemia (CLL)

• Identify the immune mediated disease-specific complications associated with CLL
• Discuss the role of thrombopoietin-like agents and other appropriate supportive care measures for the management of disease-specific complications

These objectives are subject to change as the agenda is finalized.